EVIMED 60 (Raloxifene HCl)

Manufacturer: Deus Medical

Pack: 1 Box of 2x 25 Tablets (60 mg per Tablet)

Form: Oral

What Is Raloxifene HCl (EVIMED 60)?

Raloxifene Hydrochloride is a compound classified as a Selective Estrogen Receptor Modulator (SERM).² It is a third-generation SERM that is often considered to be more tissue-selective than older SERMs like Tamoxifen (Nolvadex).

Raloxifene works by selectively acting as an estrogen receptor antagonist (blocker) in some tissues (like breast tissue) while acting as an agonist (activator) in other tissues (like bone).³

Core Functions for Bodybuilders

While Raloxifene is clinically used to prevent and treat osteoporosis in postmenopausal women, its primary utility in the context of performance enhancement is highly targeted:

• Gynecomastia Treatment: Raloxifene is considered one of the most effective prescription options for treating existing gynecomastia (gyno). Research suggests it is highly effective at reducing the size of developing gynecomastia tissue by blocking estrogen's effects on the breast.

• Bone Health Support: Due to its agonist effect in bone tissue, it helps maintain bone density, which can be beneficial during cycles that might negatively impact bone mineral content.⁴

• Alternative to Tamoxifen: It is often utilized by individuals who cannot tolerate the side effects of Tamoxifen (Nolvadex) but still require breast tissue protection.

Usage and Dosage Protocols

Raloxifene is typically used to address specific needs rather than as a general PCT component.

• Gynecomastia Management: Dosages for treating developing or existing gynecomastia symptoms typically range from $30 \text{ mg}$ to $60 \text{ mg}$ per day.

• Duration: Treatment cycles for gynecomastia are often prolonged, running for 3 to 6 months to achieve optimal reduction or reversal of the breast tissue.

• Administration: Typically taken once daily.⁵

 Side Effects and Precautions

Raloxifene is generally well-tolerated, but its selective action means it carries specific risks that must be understood.

• Deep Vein Thrombosis (DVT) Risk: The most significant concern with Raloxifene is a slightly increased risk of blood clotting events (thromboembolism), including deep vein thrombosis (DVT) and pulmonary embolism.⁶

• Common Side Effects: Hot flashes, flu-like symptoms, and leg cramps are the most common reported side effects.

• Hormonal Impact: While it blocks estrogen in the breast, Raloxifene has a less pronounced effect on stimulating the release of LH/FSH (testosterone restoration) compared to Clomiphene or Tamoxifen, limiting its effectiveness as a sole agent for PCT.

Frequently Asked Questions (FAQs)

1. How does Raloxifene (EVIMED) differ from Tamoxifen (Nolvadex) for gynecomastia?

Both are SERMs that block estrogen at the breast. However, Raloxifene is often cited in research as being more potent and effective than Tamoxifen at reducing the size of existing gynecomastia tissue, making it the preferred choice for therapeutic treatment rather than just prevention.

2. Is Raloxifene suitable as a sole agent for Post Cycle Therapy (PCT)?

No. While Raloxifene blocks estrogen receptors in the breast, it has a weaker stimulatory effect on the production of LH and FSH compared to Clomiphene or Tamoxifen. Therefore, it is generally not recommended as the sole agent for PCT, where the primary goal is to fully restore natural testosterone production.

3. What is the major health risk associated with using Raloxifene?

The major risk is an increased chance of thromboembolism (blood clots), including DVT and pulmonary embolism.⁷ Individuals with a history of blood clots or heart issues should strictly avoid Raloxifene, and all users should stay well-hydrated and monitor for symptoms.

4. Should Raloxifene be used during or after a steroid cycle?

Raloxifene can be used during a cycle for gyno prevention if Tamoxifen is not tolerated. However, its most common and valuable use is after the cycle (or post-PCT) as a therapeutic treatment for a prolonged period (3–6 months) to reverse the formation of existing gynecomastia.